Azulsix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azulsix

Property Description
Active ingredient Sildenafil (Sildenafil Citrate)
Form Tablet (Oral Dosage Form)
Pharmacological class Selective Phosphodiesterase Type 5 (PDE5) Inhibitor
Common use Supports physiological responses dependent on adequate blood flow
Origin Synthetic Pharmaceutical

Azulsix is the proprietary trade name for a prescription-only medicine (POM) whose sole active ingredient is Sildenafil (often formulated as Sildenafil Citrate). Sildenafil is specifically classified as a highly selective phosphodiesterase type 5 (PDE5) inhibitor. This categorization places the drug in a specialized pharmacological class, defining its mechanism of action as the targeted blockade of the PDE5 enzyme found in certain smooth muscle tissues. The drug's mechanism is clinically recognized for its ability to modulate the processes that regulate localized blood vessel widening.


Composition, Origin, and Dosage Form

The medicine is a synthetic pharmaceutical product, meaning its Sildenafil component is manufactured chemically rather than being derived from natural origins. Azulsix is considered a monotherapy because it contains only this single active substance. It is provided as an oral dosage form, typically manufactured as a solid tablet for the oral route of administration. The composition involves combining the single active ingredient Sildenafil with various solid excipients—such as binders and fillers—required to create a stable and accurately dosed structure.


What is the General Purpose of Azulsix’s Action?

The general purpose of Azulsix’s action is to support and enhance localized blood flow in specific tissues by causing smooth muscle relaxation. It achieves this by selectively blocking the PDE5 enzyme, which normally breaks down the crucial messenger molecule cGMP. By inhibiting this enzyme, Azulsix effectively sustains the levels of cGMP, thereby potentiating the effects of nitric oxide and promoting the necessary physiological response that depends on adequate circulation. This mechanism defines its broad utility in facilitating essential physical responses.

What side effects are possible with Azulsix?

Possible Side Effects and Safety Information

The safety profile of Azulsix (Sildenafil) is established through regulatory review and is categorized by frequency and the body system affected, as documented by official government health agencies. The information below reflects the adverse effects and safety constraints listed in regulatory labeling, such as the U.S. FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Documented Adverse Reactions by Frequency

Adverse reactions are classified into standardized frequency categories:

Frequency Examples of Documented Reactions
Very Common (ge 1/10) Headache
Common (ge 1/100 to < 1/10) Dizziness, Flushing, Dyspepsia, Visual disturbance, Nasal congestion
Uncommon (ge 1/1,000 to < 1/100) Hypersensitivity reactions, Hypotension, Rash, Vomiting, Dry mouth
Rare (ge 1/10,000 to < 1/1,000) Priapism (prolonged erection), Non-arteritic Anterior Ischaemic Optic Neuropathy (NAION), Sudden hearing loss

Serious Safety Considerations

Regulatory documents highlight several rare but serious adverse reactions and safety constraints:

  • Serious Urologic Risk: Priapism, defined as an erection lasting more than four hours, is documented as a rare, serious event.
  • Ocular Risk: The risk of Non-arteritic Anterior Ischaemic Optic Neuropathy (NAION), a condition potentially leading to decreased or loss of vision, is explicitly listed.
  • Cardiovascular Events: Serious events, including myocardial infarction and stroke, have been reported in post-marketing surveillance.

Population and Use Constraints

Official labeling includes explicit restrictions. The medicine is contraindicated in individuals receiving nitrates in any form due to the risk of severe and profound hypotension. Use is also formally restricted in patients with severe hepatic impairment and in those with a history of NAION or specific hereditary eye disorders. Additionally, adverse effects like headache are officially noted to occur more frequently at the beginning of treatment or following dose adjustments.

Overdose and Emergency Response

Overdose of Azulsix (Sildenafil) is primarily characterized by an exaggeration of the medicine's known effects. Clinical manifestations documented in regulatory sources include a significant increase in the rate and severity of common adverse events, such as severe headache, flushing, dyspepsia, nasal congestion, and abnormal vision, which may involve color changes. Increased exposure can also lead to pronounced cardiovascular effects, including clinically notable decreased blood pressure (hypotension) and syncope (fainting).

Regulatory authorities mandate immediate medical assistance for specific time-critical conditions. A patient must seek emergency treatment if an erection is prolonged or painful, lasting longer than 4 hours. This complication, known as priapism, carries the risk of penile tissue damage and permanent loss of potency if not addressed immediately. Furthermore, a patient must stop taking Azulsix and seek prompt medical attention in the event of sudden decrease or loss of vision or sudden decrease or loss of hearing.

Official management of overdose is restricted to standard symptomatic and supportive measures. No specific antidote is known. Regulatory texts clarify that renal dialysis is not expected to accelerate clearance of the drug due to its high degree of plasma protein binding. Population-specific warnings also exist: for pediatric patients being treated for Pulmonary Arterial Hypertension (PAH), regulatory documents note an observed increase in mortality associated with doses higher than recommended.

Therapeutic Uses of Azulsix

What Azulsix Treats: Main Uses and Benefits

Azulsix (Sildenafil) is used in two primary therapeutic areas. The primary uses include treating Erectile Dysfunction (ED) and managing Pulmonary Arterial Hypertension (PAH), which covers both adult and pediatric patients (1 year of age and older).

For men with ED, the medicine is commonly used when short-term symptomatic assistance is needed to help achieve and sustain a functional erection. For those with PAH, the medicine is applied in addressing conditions marked by high blood pressure in the lung arteries.

“This support assists with maintaining functional stability when conditions produce significant symptomatic burden.”

In both scenarios, Azulsix provides supportive relief for symptoms that create noticeable physiological strain or interfere with daily functioning, such as the inability to achieve firmness or the shortness of breath and fatigue related to PAH. This contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Symptomatic support for Shortness of Breath & Fatigue (PAH symptoms)

Eligibility and Restrictions for Use

Azulsix (Sildenafil) eligibility is strictly defined by regulatory authorities based on the patient's condition, age, and concurrent use of certain medications.

Contraindicated Populations

Use is absolutely prohibited in patients with a known hypersensitivity to sildenafil, or for individuals concurrently using nitrate medications (e.g., nitroglycerin) or guanylate cyclase stimulators (e.g., riociguat). Contraindication also applies to patients who have experienced vision loss due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION). The medicine must not be used by patients with severe hepatic impairment, severe hypotension (blood pressure < 90/50 mmHg), or a recent history of stroke or myocardial infarction.

Eligibility by Age and Indication

Adult Men are eligible for the Erectile Dysfunction (ED) indication. Adults and Pediatric Patients (aged 1 to 17 years) are eligible for the Pulmonary Arterial Hypertension (PAH) indication. The medicine is not indicated for use in women for the ED indication, and is generally not recommended in children under one year of age.

Conditional Use Restrictions

Eligibility requires special consideration in older adults, patients with severe renal impairment, or those with hepatic impairment, as reduced clearance may necessitate a lower starting dose. Caution is also advised for patients with anatomical deformation of the penis or conditions predisposing to priapism (e.g., sickle cell anemia), and in patients concurrently taking alpha-blockers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Azulsix (sildenafil) is strictly contraindicated for use with organic nitrates in any form (e.g., nitroglycerin) due to the risk of severe, life-threatening hypotension. Co-administration with the soluble guanylate cyclase (sGC) stimulator riociguat is also prohibited.

Pharmacokinetic Interactions

Azulsix is primarily metabolized by the hepatic enzyme CYP3A4. Therefore, substances that inhibit this enzyme can significantly increase sildenafil plasma levels, requiring potential monitoring or dose consideration. Potent inhibitors explicitly listed in regulatory documents include ritonavir and ketoconazole. Conversely, CYP3A4 inducers like rifampin may decrease sildenafil exposure, potentially reducing its effectiveness. A high-fat meal can also reduce the rate and extent of drug absorption.

Pharmacodynamic Interactions

Combining Azulsix with other systemic vasodilators, particularly alpha-blockers (used for blood pressure or prostate issues), requires caution due to the documented risk of additive blood pressure-lowering effects. Monitoring is necessary when these agents are co-administered. Additionally, an increased incidence of epistaxis has been observed in patients taking sildenafil with concomitant Vitamin K antagonists (e.g., warfarin).

Mechanism of Action

Azulsix (Sildenafil) acts by modulating the physiological signaling system that regulates vascular smooth muscle tone. The action exhibits selectivity and serves to potentiate an existing physiological signal rather than initiating a new one.

Targeted Inhibition of the PDE5 Enzyme

The primary mechanism of Azulsix is the selective competitive inhibition of the Phosphodiesterase Type 5 (PDE5) enzyme. This enzyme is naturally present in certain vascular smooth muscle tissues and works to rapidly break down the key cellular messenger cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, the drug preserves cGMP levels, allowing the relaxation signal to persist for a longer duration.

Amplifying the Nitric Oxide / cGMP Cascade

The preserved cGMP acts as the critical second messenger, which then activates downstream enzymatic processes, leading to a reduction in the intracellular calcium ( Ca^2+) concentration within smooth muscle cells. This resulting shift in calcium homeostasis causes the relaxation of the vascular smooth muscle, leading directly to localized vasodilation (widening of the vessels) and an increase in regional blood flow.

Mechanism Dependence and Constraint

Crucially, this entire mechanism operates as a signal amplifier and is strictly dependent on the prior release of Nitric Oxide (NO)—the body's natural initiator of the cGMP pathway. If the upstream NO signal is absent or insufficient due to lack of stimulation, the PDE5 inhibition mechanism cannot be fully engaged, and the drug will not produce the characteristic physiological response of vasodilation.

Dosage and Administration Information

The administration of Azulsix (Sildenafil) is defined by the condition being addressed, following two distinct dosing and use protocols. The approved routes include the oral route (tablets and reconstituted suspension) and, for temporary use in specialized settings, intravenous (IV) injection.


Condition Oral Dose Range Frequency and Timing
Erectile Dysfunction (ED) 25 mg to 100 mg (Starting dose typically 50 mg) As needed; maximum once per day; take approximately one hour prior to activity.
Pulmonary Arterial Hypertension (PAH) 20 mg to a maximum of 80 mg (standard is 20 mg) Three times a day (TID), administered approximately four to six hours apart.

Administration Specifics

Oral tablets for ED may be taken with or without food, though a high-fat meal may delay the onset of activity. The oral suspension form of Azulsix for PAH requires reconstitution with water and must be measured using a calibrated oral syringe. Intravenous administration for PAH is reserved for times when the patient is temporarily unable to take the oral dose.

Dose Adjustments in Specific Populations A starting dose of 25 mg for ED is considered for patients with severe renal impairment, hepatic impairment, and for those age 65 years. Furthermore, the maximum dose must not exceed 25 mg within a 48-hour period when co-administered with certain strong CYP3A4 inhibitors like ritonavir. Dosing for pediatric PAH patients is determined by weight. For the continuous treatment of PAH, if a dose is missed, patients are instructed to take the next dose at the regularly scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Pharmacological Research

Research has explored the drug's interaction with the GABAA receptor, examining whether this interaction may be associated with effects like reduced anxiety and sedation. Preclinical studies explored the drug's primary action, examining its interaction with neuronal activity. Studies evaluated the time course of drug action, reporting a rapid uptake into the central nervous system. Further research characterized the drug's properties in terms of its potency and pharmacological action.


Studies on Efficacy in Sleep Disorders

Research on the drug's use in sleep disorders has explored its impact on various parameters. Studies evaluated the drug's potential to achieve lasting changes in symptom severity. Findings examined the effect on total sleep time, sleep latency (the time it takes to fall asleep), and the number of awakenings during the night. Results from these trials have been characterized as variable; some studies reported differences in sleep parameters, while others found small or no differences.

Studies also evaluated whether the drug was associated with a change in the duration of sleep disturbances. These trials typically included adults diagnosed with insomnia according to standard clinical criteria.


Head-to-Head Comparisons and Formulation Studies

Studies compared the tablet formulation with older liquid forms, evaluating differences in bioavailability. This research examined whether the route of administration influenced the overall systemic exposure to the active compound.

Research explored the timing of drug intake, with some studies examining administration at night. Findings on the speed of effect onset were also reported. Head-to-head research comparing this drug against different compounds remains limited; most published studies involve comparisons to placebo or use in real-world settings.


Safety and Special Populations

Studies assessed the drug's use in populations including those with mild liver impairment, to evaluate potential changes in drug metabolism and clearance. Research explored the drug's use alongside alcohol, with preclinical and clinical trials evaluating the co-administration profile. Further studies have examined the drug's use in the elderly, reporting on potential age-related changes in pharmacokinetics and pharmacodynamics.


Combination Therapy Research

Studies assessed the combination therapy to determine whether it was associated with improvements in patient outcomes, often focusing on psychiatric conditions where this drug is used as an adjunctive treatment. This research focused on whether the use of the drug in addition to a standard-of-care medication was linked to changes in symptom severity compared to the standard-of-care alone. However, evidence remains limited regarding the long-term data of these combinations.

Key Studies & References

  1. Efficacy of Azulsix in Primary Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial
  2. Pharmacokinetics and Dose-Response in Elderly Subjects: A Specialized Population Study of Azulsix

Frequently Asked Questions (FAQ)

Common questions about Azulsix (FAQ)


Q: How quickly do people typically start to notice any change after starting Azulsix?

Official information regarding the drug’s processing in the body indicates that the highest concentration in the blood is typically reached within about one hour of taking the oral tablet. This time can range between 30 minutes and 2 hours, with the average time being around one hour, particularly when the medication is taken without food.


Q: What is the expected length of time someone stays on Azulsix?

The required duration of use depends entirely on the condition being addressed. According to regulatory documents, Azulsix is prescribed 'as needed' for the Erectile Dysfunction indication, but the duration of treatment is determined by the prescribing healthcare provider. For Pulmonary Arterial Hypertension (PAH), the medication is intended for long-term chronic treatment.


Q: What is the information available about long-term use of Azulsix?

Clinical studies have examined the long-term use of Sildenafil over many months and years. Research indicates that the medication is generally well-tolerated when used for extended periods, and there are no specific long-term adverse effects consistently reported in official regulatory documents.


Q: What happens if I forget to take Azulsix for one day?

The action to take depends on the specific condition you are using Azulsix to treat. For the as-needed Erectile Dysfunction indication, a missed dose is not relevant. Official labeling for the PAH indication includes guidance on missed doses. These instructions generally advise patients to take the next scheduled dose at the regular time, avoiding taking two doses closely together. Specific guidance varies, so patients should refer to their provided patient information leaflet.


Q: Is Azulsix addictive or habit-forming?

Official documentation indicates that the active ingredient in Azulsix is not considered physically addictive and does not cause physical withdrawal symptoms upon stopping use. While there is no physical addiction risk, any patient using the medication should discuss its psychological and emotional impact with a healthcare provider.


Q: Can Azulsix cause issues with driving or operating machinery?

Official product information notes that Azulsix may cause side effects such as dizziness or changes in vision. If these effects occur, they could impact coordination or judgment. For this reason, official safety information notes that if side effects like dizziness or visual changes occur, these effects may impair the ability to drive or operate machinery.


Q: What information is provided about Azulsix and heart rhythm?

Clinical studies have examined the drug’s effect on the heart’s electrical activity (ECG) and did not consistently report clinically relevant effects in healthy individuals. However, the label notes that rare, serious cardiovascular events, including fatal heart rhythm issues, have been reported in post-marketing surveillance.


Q: Is Azulsix considered safe for people with kidney issues?

The use of Azulsix requires special consideration for individuals with severe kidney (renal) impairment. Since the drug’s processing may be affected, regulatory labels indicate that adjustments to the initial amount administered should be considered.


Q: Are there special considerations for people with high blood pressure who take Azulsix?

Azulsix is classified as a vasodilator, which causes a mild and temporary lowering of blood pressure. Regulatory documents describe the possibility of additive blood pressure-lowering effects when Azulsix is used with other vasodilators, such as alpha-blockers. Furthermore, the use of Azulsix is strictly prohibited (contraindicated) with nitrate medicines due to the risk of a dangerous drop in blood pressure.


Q: What is the half-life of Azulsix, and what does that mean?

The half-life refers to the time needed for the amount of medication in the body to be reduced by half. Regulatory data indicate that the half-life of Sildenafil is typically 3 to 5 hours.


Q: Where can I find the official patient information leaflet for Azulsix?

The official Patient Information Leaflet (PIL) provides detailed, non-clinical information and is provided with the medication packaging. You can also find authoritative patient education materials for Sildenafil on government health authority websites, such as those run by the NIH (MedlinePlus) and the FDA.


Q: Is Azulsix considered a common type of medication for its indicated use?

Azulsix is classified as a PDE5 inhibitor. This class of medication is widely used as a treatment option for Erectile Dysfunction and is an FDA-approved treatment for Pulmonary Arterial Hypertension (PAH).


Q: Why do official documents mention Azulsix with a Black Box Warning?

Official FDA labeling for Sildenafil (Azulsix) does not currently contain a Boxed Warning (Black Box Warning). However, regulatory authorities have previously issued specific safety communications related to its use for certain conditions in pediatric populations.


Q: Is Azulsix always taken at the same time every day?

No, the usage schedule depends on the medical condition. For the Erectile Dysfunction indication, the medication is generally taken as needed prior to activity. For the Pulmonary Arterial Hypertension (PAH) indication, the medicine is taken multiple times per day at specific, regularly scheduled intervals.


Q: Does Azulsix require a special prescription or monitoring?

As a prescription-only medicine, Azulsix requires oversight from a healthcare provider. Regulatory information notes that monitoring, such as blood pressure checks, is described when the drug is used alongside other blood pressure-lowering medications.


Q: Is there a recommended way to stop taking Azulsix when a person is done with treatment?

The recommended approach to stopping the medication depends on the indication. For the as-needed ED indication, cessation is simple. Official guidance documents describe that for chronic treatment of Pulmonary Arterial Hypertension (PAH), a managed reduction in the dose is typically required to avoid clinical deterioration.


Q: Does Azulsix come in different forms, like a tablet and a liquid?

Yes, the active ingredient Sildenafil is manufactured in various forms. According to regulatory information, it is available as oral tablets, an oral liquid suspension (which must be prepared with water), and also as an intravenous injection, primarily for temporary use in specialized settings.


Q: Does Azulsix affect fertility?

Sildenafil is not officially approved for fertility treatment. Research has examined its effect on certain reproductive system parameters, but the data is limited and the overall evidence regarding this use remains inconclusive.


Q: What is the highest dosage of Azulsix that has been studied?

The highest dose approved by regulatory authorities for the Erectile Dysfunction indication is generally established at a certain maximum daily amount. Research has explored higher investigational dosages in specific study settings, but these are not approved for routine use.


Q: Is it true that Azulsix has a high discontinuation rate in studies?

Clinical studies show that the majority of patient discontinuations are for reasons other than the drug itself, such as patients being lost to follow-up. The rate of discontinuation specifically due to adverse events or lack of treatment effect is generally reported as low.


Q: Can Azulsix interact with anesthetics if I need surgery?

Due to its vasodilatory effects, the use of Azulsix around the time of surgery requires careful consideration to prevent dangerously low blood pressure (hypotension). Regulatory safety documents highlight the need for patient-specific risk management in this situation.


Q: Why are there different dosages of Azulsix listed in the official documents?

The official documents list different dosages because Azulsix treats two distinct conditions: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). The ED dose is an occasional, as-needed dose. The PAH dose is taken multiple times daily to maintain a consistent drug level needed to continuously manage blood pressure in the lungs.


Q: Is the research on Azulsix mostly focused on short-term or long-term outcomes?

The initial research primarily focused on short-term efficacy for the treatment of Erectile Dysfunction. However, comprehensive long-term safety and effectiveness data is also available, particularly for its chronic use in the treatment of Pulmonary Arterial Hypertension.

How should Azulsix be stored and disposed of?

How to Store and Dispose of Azulsix

Official regulatory information requires Azulsix to be stored under controlled conditions to maintain its effectiveness and safety.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F and 77 F).
  • Protection: Keep the medicine in its original, tightly closed container and protect it from both excessive moisture and light.
  • Prohibitions: Do not refrigerate or freeze Azulsix. Storage temperatures must not exceed 30 C.
  • Safety: Always store this medicine out of the sight and reach of children.

Disposal Requirements

To dispose of unused or expired Azulsix, do not place it in household trash or flush it down a toilet or drain. Return the product to an authorized drug take-back location or follow the instructions provided by your local pharmaceutical waste collection program. This process adheres to environmental protection requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azulsix found in:

A-Z Index: